Axicabtagene ciloleucel
Gilead,Daiichi Sankyo
[]
 the old 40% rule.
Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.